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Abstract: Patients with irritable bowel syndrome (IBS) are suggested to have an altered intestinal
microenvironment. We therefore aimed to determine the intestinal microenvironment profile, based
on faecal microbiota and metabolites, and the potential link to symptoms in IBS patients. The
faecal microbiota was evaluated by the GA-mapTM dysbiosis test, and tandem mass spectrometry
(GC-MS/MS) was used for faecal metabolomic profiling in patients with IBS and healthy subjects.
Symptom severity was assessed using the IBS Severity Scoring System and anxiety and depression
were assessed using the Hospital Anxiety and Depression Scale. A principal component analysis
based on faecal microbiota (n = 54) and metabolites (n = 155) showed a clear separation between IBS
patients (n = 40) and healthy subjects (n = 18). Metabolites were the main driver of this separation.
Additionally, the intestinal microenvironment profile differed between IBS patients with constipation
(n = 15) and diarrhoea (n = 11), while no clustering was detected in subgroups of patients according
to symptom severity or anxiety. Furthermore, ingenuity pathway analysis predicted amino acid
metabolism and several cellular and molecular functions to be altered in IBS patients. Patients
with IBS have a distinct faecal microbiota and metabolite profile linked to bowel habits. Intestinal
microenvironment profiling, based on faecal microbiota and metabolites, may be considered as a
future non-invasive diagnostic tool, alongside providing valuable insights into the pathophysiology
of IBS.
Keywords: irritable bowel syndrome; pathophysiology; intestinal microenvironment; microbiota;
microbial metabolites
1. Introduction
Irritable bowel syndrome (IBS) is a multifactorial disease involving a perturbed gut–
brain interaction [1], visceral hypersensitivity [2], altered gastrointestinal (GI) motility [3],
increased permeability, immune activation [4] and an altered gut microenvironment [5].
Currently, the diagnosis of IBS is based on symptom-based criteria, and in most cases, a
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limited number of tests are carried out to exclude other organic GI diseases [6]. However,
reliable disease-specific biomarkers for IBS are still lacking [6].
The microbiota inhabiting the human GI tract coexist under a mutualistic relationship
and benefit the host by participating in immunity, resistance to pathogen colonization and
intestinal development [7,8]. The gut microbiota produces a diverse range of metabolites
from the anaerobic fermentation of exogenous undigested dietary compounds. These small
and diverse molecules reach the colon and are used as energy sources and substrates in
metabolic or signalling pathways, as well as influencing host immune response [9,10], re-
flecting the hosts’ physiological status [11]. Metabolites may be regarded as a “fingerprint”
of the functional interactions taking place between the host and microbiota [9]. Recent
studies have described an altered composition of gut microbiota and metabolites in several
diseases of the GI tract such as colorectal cancer and inflammatory bowel disease [11,12]. In
addition, IBS has been linked to an unbalanced gut microbiota profile [13–16] and possibly
also to an altered metabolite profile [17,18], with links to GI [17,19] and psychological
symptoms [20], at least in subsets of patients. There are also contradictory reports of lower,
as well as higher, concentrations of faecal short-chain fatty acids in IBS with diarrhoea
(IBS-D) as compared to healthy subjects [21]. However, no clear differences have been
depicted in the microbiome or metabolome profiles between IBS subtypes [22]. The pub-
lished data within the field are still relatively limited and studies combining analyses of
faecal microbiota and metabolites are rare and inconclusive [22–26]. Despite inconsisten-
cies, the overall picture indicates that subsets of IBS patients have an altered intestinal
microenvironment [27].
We hypothesized that the intestinal microenvironment differs between IBS patients
and healthy subjects. Analyses of the joined faecal microbiota and metabolite composition
may provide valuable insights into host–microbiota interactions and how these interactions
can play a role in the pathophysiology of IBS. In this study, we aimed to determine the
intestinal microenvironment, based on both faecal microbiota and metabolites, and its link
to bowel habits, symptom severity and psychological symptoms in patients with IBS.
2. Materials and Methods
2.1. Study Cohort
This is a retrospective study analysing faecal samples collected from IBS patients
and healthy subjects recruited as described previously [16,28]. Briefly, IBS patients (18–
70 years old) meeting the Rome III criteria [29] were recruited from patients referred to the
gastroenterology outpatient clinic at the Sahlgrenska University Hospital, Gothenburg, as
well as through advertisement in local newspapers. Exclusion criteria were the presence of
severe diseases such as malignancy, heart disease, kidney disease; neurological or psychi-
atric diseases; or a GI disease other than IBS that could explain their current symptoms
(e.g., inflammatory bowel disease, coeliac disease). Patients on special diets such as the
low FODMAP diet and low fibre diet were not included in the study. IBS patients were
characterized as having IBS with constipation (IBS-C), diarrhoea (IBS-D) [29], mixed IBS
(mixed loose and hard stools) (IBS-M) or unclassified IBS (IBS-U) by evaluation of bowel
movements (number of stools per day) and stool consistency according to Bristol Stool
Form (BSF) scale in a two-week stool diary. For analyses, the last two subtypes, IBS-M and
IBS-U, were grouped together as IBS-nonCnonD [29].
All IBS patients completed validated self-report questionnaires assessing the severity
of their IBS symptoms (IBS Severity Scoring System; IBS-SSS) [30], and anxiety and de-
pression (Hospital Anxiety and Depression Scale; HADS) [31]. These questionnaires have
validated cut-off levels used to categorize patients according to symptom severity and
the presence or absence of anxiety or depression, respectively [30,32] (see Supplementary
Material for more details). Healthy subjects (18–70 years old) with no current or prior
history of GI diseases were included as controls. Chronic disorders, use of any immunosup-
pressive agents, antibiotics or any other medication during the 3 months prior to sample
collection, and being on restrictive diets (i.e., vegan, glute-free and lactose-free diet), were
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reasons for exclusion from the healthy cohort. The use of other special diets was recorded
as previously shown [16]. Pregnant or lactating women were not included. Additionally,
all study subjects were requested to abstain from the intake of pre- and probiotics. All
IBS patients and healthy subjects were given verbal and written information before giving
their written consent to participate in the study. The study protocol was approved by the
Regional Ethical Review Board in Gothenburg. All authors had access to the study data
and have reviewed and approved the final manuscript.
2.2. Faecal Sample Collection
Faecal samples were collected by all study subjects at home. Study subjects were
provided with faecal sample collection kits, including an empty tube and a sampling
spatula. Samples were kept in a freezer at −20 ◦C until being transferred to the laboratory
in a mini cooler bag with an ice pack. Samples were stored in the laboratory at −80 ◦C until
analysis. All samples were analysed for microbiota and metabolomics profiles, respectively.
2.3. Faecal Microbial Analysis
Bacterial populations were detected at Genetic Analysis AS (Oslo, Norway) using the
commercially available analysis, the GA-map™ dysbiosis test. The GA-mapTM test targets
≥ 300 bacteria belonging to different taxonomic levels by using a set of 54 highly specific
DNA probes previously defined to discriminate between healthy subjects and patients with
IBS in faecal samples. The protocol is described in detail elsewhere [33]. Briefly, this test
includes faecal sample homogenization, mechanical bacterial cell disruption and automated
total bacterial genomic DNA extraction with magnetic beads. Amplification of 16S rRNA
(V3–V9 regions) is performed by polymerase chain reaction (PCR), followed by a single-
nucleotide extension reaction. In this step, the complementary PCR amplicon hybridizes
with a labelling probe, which is then extended with a labelled nucleotide. Subsequent
addition of complementary probes coupled with magnetic beads hybridize to the labelled
probes. This last hybridisation provides the signal from the nucleotide labelled-labelling
probes that is acquired by the BioCode 1000A 128-Plex Analyzer (Applied BioCode, Santa
Fe, CA, USA). This signal corresponds to the bacteria present in the sample, which are
identified with the help of magnetic beads [33]. As a result, the GA-mapTM test generates a
bacterial profile based on absolute faecal bacterial abundance, which is denoted as probe
signal intensity [33].
2.4. Faecal Supernatant Preparation and Metabolite Analysis
Faecal supernatants extracted from faecal samples were used for metabolomics analy-
sis. Faeces were mixed with 2 weight volumes of ice-cold PBS, followed by centrifugation
for 10 min at 1600× g. The resulting supernatant was ultra-centrifuged at 35,000× g
for 2 h, at 4 ◦C. The faecal supernatants were collected and stored at −80 ◦C until anal-
ysis. The metabolomic profile of faecal supernatant samples was analysed using gas
chromatography coupled to a tandem mass spectrometer (GC-MS/MS) using the method
of Savolainen et al. [34]. Briefly, samples were extracted with water:methanol (1:9 v/v)
containing ten stable isotope labelled internal standards [34], followed by drying and
derivatization by using oxymation and silylation. The derivatised extracts were injected
into a GC-MS/MS system (Shimadzu GCMS TQ-8030 system, Shimadzu Europa GmbH,
Duisberg, Germany) and GC-MS scan data (between m/z 50–750) were analysed for tar-
geted peak detection. Metabolites present in the Swedish Metabolomics Centre library were
screened against the scan data using a Matlab script (Mathworks, Natick, MA, USA) and
database developed at the Swedish Metabolomics Centre (Umeå, Sweden). This uses the
retention index, diagnostic ion and spectral matching to score and identify likely metabo-
lites. Peaks were visually inspected to ensure they were correct. Data were normalized
based on the internal standard peak intensities [35].
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2.5. Statistical Analyses
Univariate statistical analysis was performed using the SPSS Statistical Package (IBM
Corp. Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Alrmonk, NY, USA:
IBM Corp.). Categorical variables were compared with the χ2 test, whereas continuous
variables were compared using either the independent samples and paired samples t-test
or the corresponding non-parametric Mann–Whitney U test and Wilcoxon signed rank
test, based on the normality of distribution determined by histograms and Kolmogorov–
Smirnov statistic tests. The data in text, figures and tables are shown, corresponding to the
distribution, as mean ±SD or median (interquartile range), respectively. p values < 0.05
were considered statistically significant.
Multivariate analyses were applied to the combined dataset containing faecal micro-
biota and metabolites data. Principal component analysis (PCA) was conducted using the
prcomp-function with z-score scaling, and visualized using the pca3d-package in R (version
3.6.2, Vienna, Austria) [36]. The multivariate group means were represented as centroids.
To test the statistical significance of comparisons between the two groups (e.g., IBS vs.
healthy), i.e., whether the groups differed in their mean scores on the two principal compo-
nents, we iteratively randomized the group labels to simulate a null-distribution of centroid
differences, and ranked the actual value within this null-distribution. p values < 0.05 were
interpreted as significantly different multivariate group means. Orthogonal partial least
squares-discriminant analysis (OPLS-DA) was implemented to investigate if the combined
dataset, containing faecal microbiota and metabolites profiles (X variables), could discrim-
inate IBS patients from healthy subjects (Y variables). All discriminant analyses were
performed using SIMCA® software (version 15.0.2, MKS Umetrics AB, Umeå, Sweden).
The quality of OPLS-DA was determined based on the parameters R2, i.e., the goodness of
fit of the model (values of ≥0.5 define good discrimination, where R2 = 1 is the best possible
fit), and Q2, i.e., the goodness of prediction of the model (values of ≥0.4 are considered
good) [37]. The reliability of the models was confirmed using analysis of variance testing
of cross-validated predictive residuals (CV-ANOVA), where a p value < 0.05 indicated
significantly different residuals of the compared groups. Student’s t-test was used to verify
the robustness of the selected variables from the simplified OPLS-DA model.
Volcano scatter plots were used for the identification of differentiating faecal mi-
crobiota and metabolites for which the fold change for each metabolite and bacterial
taxon between IBS patients and healthy subjects was calculated, i.e., (metabolite A in
IBS/metabolite A in healthy) and (bacterial taxon A in IBS/bacterial taxon A in healthy).
Significance (–log10 (p value < 0.05), Student’s t-test) versus log2 (mean fold change) [38]
were plotted, and only most relevant variables were labelled. Visualization was performed
in R using the ggplot2 and ggrepel packages. Further, Cleveland plot analysis was performed
in R using the ggplot2, dplyr and tidyr packages.
In addition, the least absolute selection and shrinkage operator (LASSO) method with
regularization was used to extract a set of most relevant discriminative variables amongst
microbial taxa and metabolites to help distinguish IBS patients from healthy subjects and
further facilitate the interpretability of our findings by simplifying our model. LASSO was
performed using the caret [39] and glmnet [40] packages in R and is described in detail in
the Supplementary material.
The ingenuity pathway analysis (IPA, version 2.3) (Qiagen Inc., https://www.qiag
enbio-informatics.com/products/ingenuitypathway-analysis, trial version accessed on
18 March 2020) [41] was used to identify biological networks associated with mean fold
change values (IBS patients/healthy subject) for each of the analysed faecal metabolites.
A p value < 0.05 was set as the cut-off and activation z-scores were calculated and used
to predict increased (z-score > 2.0) or decreased (z-score < −2.0) biological functions that
could explain the differences on the metabolite dataset.
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3. Results
3.1. Characteristics of the Study Cohort
The study cohort consisted of 40 IBS patients and 18 healthy subjects. The demo-
graphics and clinical characteristics of the study subjects are shown in Table 1. Females
and males were unequally distributed between the study groups, and healthy subjects
were younger than IBS patients (p < 0.001). All IBS subtypes (IBS with diarrhoea or IBS-D,
IBS with constipation or IBS-C; and IBS-nonCnonD or combined mixed-type IBS and IBS
unclassified) were represented in the study population. The majority of patients presented
with moderate to severe IBS symptoms (IBS-Severity Scoring System; IBS-SSS) and had
higher Hospital Anxiety and Depression Scale (HADS) total scores than healthy subjects.
Likewise, a higher proportion of individuals with anxiety was found among the IBS pa-
tients compared to healthy subjects, whereas the proportion of individuals with depression
did not differ between the two groups.
Table 1. Demographics and clinical characteristics of the study cohort.
Baseline Characteristics IBS (n = 40) Healthy (n = 18) p Value
Sex (F:M) 31:9 9:9 0.04
Age, years † 52 (24–70) 26 (19–54) <0.001
IBS subtypes IBS-C:IBS-D:IBS-nonCnonD 15:11:14 N/A
IBS-SSS ‡ 236 (174–327) 11 (0–20) <0.001
Mild:moderate:severe § 10:17:13 N/A
HADS total score ¶ 9.9 ± 5.9 6.8 ± 3.9 <0.05
Anxiety:no anxiety ϕ 14:17 3:15 0.04
Depression:no depression ϕ 3:28 0:18 0.17
Note: Abbreviations: N/A, not applicable; IBS-C, IBS with constipation; IBS-D, IBS with diarrhoea; IBS-nonCnonD, mixed-type IBS and
unclassified IBS; IBS-SSS, IBS Severity Scoring System; HADS, Hospital Anxiety and Depression Scale. † Data shown as median (min–max).
‡ Data shown as median (interquartile range). § Based on IBS-SSS. ¶ Data shown as mean ±SD. ϕ Based on HADS.
3.2. The Intestinal Microenvironment Differs between IBS Patients and Healthy Subjects
First, we investigated whether the intestinal microenvironment differed between IBS
patients and healthy subjects. A principal component analysis (PCA) based on the total
number of identified faecal microbiota (n = 54 variables) and metabolites (n = 155 variables)
showed a clear separation between IBS patients and healthy subjects, with a large distance
between the centroids (scores averages) of the two groups (p < 0.001) (Figure 1A). This
separation was not seen to be influenced by age and gender differences (Figure S1A,B).
An orthogonal partial least squares-discriminant analysis (OPLS-DA), based on the total
number of identified variables, further supported the differentiation seen between IBS
patients and healthy subjects (Table 2). As visualized by Cleveland plots, the majority of
the differentiating variables were found in higher abundance in IBS patients (bacterial
taxa; n = 3 and metabolites; n = 67) compared to healthy subjects (bacterial taxa; n = 5
and metabolites; n = 2) (Figure 1B, Figure S2). Furthermore, a volcano plot showed that
a large number of metabolites such as citric acid, alanine, glycine, tryptophan, xanthine,
hypoxanthine and pyruvic acid along with Acinetobacter junii were higher in IBS patients
as compared to healthy subjects, whereas only a few variables such as Clostridium sp.,
glucose-6-phosphate and nicotinic acid were found in lower abundance (Figure 1C). In
addition, LASSO variable selection identified a total of 21 variables (bacterial taxa; n = 5
and metabolites; n = 16), providing an even more robust model (accuracy of 90.9%) for
distinction of IBS patients from healthy subjects. The variables identified by the LASSO
model as being most important for the separation between IBS patients and healthy subjects
were depicted by an OPLS-DA (Figure 1D).
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subjects (n = 18, blue dots). The p value depicts statistical significance of the distance between centroids (scores average)
of the groups. (B) Cleveland dot plot depicting the differentiating microbiota and metabolite variables (p < 0.05) between
IBS patients and healthy subjects. The horizontal axis represents bacterial probe intensity (n = 14) and metabolite signal
intensity (n = 76) values and the vertical axis shows the variable IDs. Log-transformed median values for each X-variable are
depicted for the IBS group (black dots) and healthy group (grey dots), respectively. Mann–Whitney U test was performed to
evaluate differences between the groups. (C) Volcano plot illustrating mean fold change vs. statistical significance based
on 54 bacteria (probe intensity) and 155 metabolites (signal intensity) in IBS patients vs. healthy subjects (IBS/H). Each
dot corresponds to a bacterial probe or metabolite signal. Variables increased in IBS are coloured in yellow (n = 70), while
decreased variables compared to healthy subjects are coloured in blue (n = 7). Mean fold change is shown as log2. p values
are shown as –log10; p value < 0.05 are coloured; non-significant p values are shown in grey. Student’s t-test was used to
identify differences between the groups. For visual clarity, only some bacteria and metabolites with log2 (IBS/H) < −1 and
>+1 and p values < 0.05 are labelled. (D) Orthogonal partial least squares-discriminant analysis (OPLS-DA) loading column
plot based on the discriminatory bacterial taxa (n = 5) and metabolites (n = 16), selected after the least absolute selection
and shrinkage operator (LASSO) method with regularization, between IBS patients and healthy subjects. The R2 value
indicates goodness of the fit; the Q2 value expresses prediction ability. The p value depicts statistical significance based on
the cross-validated residuals (CV-ANOVA) test. Error bars indicate 95% confidence intervals. Asterisks represent significant
p-values: * < 0.05; ** < 0.01; *** < 0.001.
Table 2. Parameter values for orthogonal partial least squares-discriminant analysis (OPLS-DA) models.
OPLS-DA Model R2 Q2 p Value
IBS vs. Healthy 0.96 0.79 <0.001
IBS vs. Healthy (LASSO) † 0.86 0.78 <0.001
IBS-C vs. IBS-D 0.99 0.56 0.04
IBS-C vs. IBS-nonCnonD 0.46 0.14 0.13
IBS-D vs. IBS-nonCnonD ‡ 0.75 −0.26 >0.99
IBS mild vs. IBS moderate § 0.38 −0.005 >0.99
IBS mild vs. IBS severe ‡,§ 0.84 −0.02 >0.99
IBS moderate vs. severe § 0.42 0.05 0.52
IBS with anxiety vs. IBS without anxiety ¶ 0.72 0.12 0.51
Note: All OPLS-DA models are based on the intestinal microenvironment profile, including 54 microbial taxa and 155 metabolites analysed,
unless specified. R2 value indicates goodness of the fit of the model; Q2 value describes the prediction ability of the model. The p value
depicts statistical significance based on ANOVA of the cross-validated residuals (CV-ANOVA). Abbreviations: IBS-C, IBS with constipation;
IBS-D, IBS with diarrhoea; IBS-nonCnonD, mixed-type IBS and unclassified IBS. † IBS vs. healthy (LASSO) model based on 21 selected
variables (n = 5 bacterial taxa and n = 16 metabolites). ‡ OPLS-DA model calculated by adding two first forced components. § Based on
IBS-SSS, IBS Severity Scoring System. ¶ Based on Hospital Anxiety and Depression Scale.
3.3. The Intestinal Microenvironment Differs between IBS Subgroups
We further explored whether the intestinal microenvironment composition differed
between subgroups of IBS patients classified according to the predominant bowel habit,
symptom severity and anxiety. A PCA based on the total number of identified faecal
microbiota (n = 54) and metabolites (n = 155) showed that IBS-nonCnonD (n = 14) over-
lapped with IBS-C (n = 15) and IBS-D (n = 11) (Figure 2A), whereas patients with IBS-D
clustered separately from IBS-C with significant distance between their centroids (p < 0.001)
(Figure 2B). The separation between the predominant bowel habit subtypes was supported
by an OPLS-DA based on the total number of measured variables (Table 2). Furthermore,
a volcano plot identified the variables, mostly metabolites, which contributed to the sep-
aration between IBS-D (bacterial taxa; n = 2 and metabolites; n = 27) and IBS-C patients
(bacterial taxa; n = 4 and metabolites; n = 5) (Figure 2C). IBS-D patients were defined by
higher levels of numerous metabolites, whereas IBS-C patients were associated with higher
levels of δ-tocopherol, Mycoplasma hominins, Firmicutes A, actinomycetales and Shigella sp.
and Escherichia spp. (Figure 2C).
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In contrast, the intestinal microenvironment profile did not differ between patients 
with mild (n = 10), moderate (n = 17) and severe IBS symptoms (n = 13) (Figure 3A, Table 
2). Additionally, no clustering, based on the faecal microbiota and metabolites, was seen 
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i r 2. Faecal microbiot and metabolite profiles of IBS patients based on th predominant bowel hab t. Principal
c mponent analysis (PCA) score scatter plot based on faecal b cteria and metabolites showing (A) IBS-D (n = 11, green
triangles), IBS-C (n = 15, purple circles) and IBS-nonCnonD (n = 14, pink squares) patients and (B) patients with the
predominant bowel habit, IBS-D and IBS-C. The p value depicts the statistical significance of the distance between the
centroids (scores averages) of the groups. (C) Volcano plot illustrating statistical significance versus mean fold change
of 54 bacteria (probe intensity) and 155 metabolites (signal intensity) between IBS-D patients respect to IBS-C patients
(IBS-D/IBS-C). Each dot corresponds to a bacteria probe or metabolite signal. Variables increased in IBS-D are coloured in
green (n = 29), while decreased variables compared to IBS-C are coloured in purple (n = 9). Mean fold change is shown as
log2. p values are shown as –log10; p values < 0.05 are coloured; non-significant p values are shown in grey. Student’s t-test
was used to identify differences between the groups. Not all variables were labelled, only some bacteria and metabolites
with log2 (IBS/H) < −1 and >+1 and p values < 0.05.
In contrast, the intestinal microenvironment profile did not differ between patients
with mild (n = 10), moderate (n = 17) and severe IBS symptoms (n = 13) (Figure 3A, Table 2).
Additionally, no clustering, based on the faecal microbiota and metabolites, was seen
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between IBS patients with and without anxiety (cut-off HADS anxiety score ≥ 8) (Figure 3B,
Table 2). Too few patients met the criteria for borderline or clinically significant depression
to allow exploration of the relationship with intestinal microenvironment profile.
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4. Discussion
In this study, we demonstrated that IBS patients can be differentiated from healthy sub-
jects based on the intestinal microenvironment, comprising the combined faecal microbiota
and metabolite profiles. Additionally, we showed that IBS patients classified according to
their predominant bowel habits, but not severity of IBS symptoms or presence/absence
of anxiety, can be distinguished on the basis of the intestinal microenvironment. Further
analysis suggested that altered amino acid metabolism and certain cell signalling pathways
may be involved in the pathophysiology of IBS.
During the last decade, numerous studies have addressed the role of gut microbiota in
IBS pathophysiology [13–16]. More recently, reports focusing on intestinal metabolites [17,18],
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alongside studies integrating the gut microbiome and metabolome [22,24,25], as well as the
host epigenome and transcriptome [26], have explored host–microbiota interactions and
the link to GI symptoms in IBS patients. Our current study demonstrates that a combined
analysis of faecal microbiota and metabolite profiles separates a mixed group of IBS patients
from healthy subjects. This is in agreement with a report by Shankar et al., who previously
described this joint classifier to facilitate diagnosis of IBS and differentiate paediatric
IBS-D patients from age-matched controls [24]. Furthermore, our study demonstrated
that the combined microbiota and metabolite profiling model differentiated between IBS-
D and IBS-C patients. This finding is in line with the work by Mars et al., reporting IBS
subtype-specific and symptom-related variation in microbial composition and function [26].
Nevertheless, to emphasize the complexity of these analyses and their interpretation, there
is also a report demonstrating a lack of differences between IBS subtypes based on the
individual microbiota or metabolite profiles [22].
In this study, however, we did not detect differences in the intestinal microenvironment
profile between IBS subgroups based on IBS symptom severity. Interestingly, our group
previously demonstrated faecal bacteria to be associated with bowel habit-based IBS
subtyping, whereas mucosa-associated bacteria were linked to IBS symptom severity [16].
It may therefore be suggested that the link between the intestinal microenvironment profile
and bowel habits but not symptom severity in this study was due to the sampling site.
Faecal samples, although not fully representative of the entire GI tract, are widely used
in studies to reflect the intestinal microenvironment since they are non-invasive and easy
to collect, compared to mucosal biopsies. Moreover, the analysis techniques used in this
study to determine the microenvironment profile (GA-mapTM test and GC-MS/MS) are
both relatively easier and quick to perform. This facilitates their use in a clinical setup
in comparison to other explorative techniques, e.g., 16S rRNA gene sequencing and LC-
MS/MS. The bacterial profiles generated by the commercially available GA-mapTM test
based on faecal bacterial absolute abundance have the additional advantage of being
closely associated with gastrointestinal disorders. Thus, the combination of the accessibility
of faecal samples, and these two quick and reliable analyses may constitute an asset for
development of non-invasive diagnostic tools.
Altered production or availability of metabolites such as amino acids, short-chain fatty
acids, vitamins, bile salts, lipids and organic acids, associated with microbial metabolism
or host-microbial co-metabolism, could result in alteration of pathways involved in host
physiology [9]. Our study depicts a distinct IBS gut microenvironment characterized by
increased amino acid metabolism seen as increase in alanine, glycine and proline, and
amino acid metabolism intermediates such as phenylpyruvic acid and pyruvic acid. This
may suggest higher epithelial cell turnover processes related to low-grade inflammation
such as collagen degradation [42], potential malabsorption of amino acids [23], an increase
in protein catabolism by the gut microbiota [25] or even increased efflux of amino acids in
IBS patients. Additionally, increased levels of molecules involved in the Krebs cycle such as
α-ketoglutaric acid, citric acid and pyruvic acid, but also hypoxanthine and xanthine, which
are metabolic forms of purines, known to promote intestinal barrier development [43],
were recorded in patients with IBS. This may indicate an altered energy metabolism and
proliferation or degradation of bacterial and/or epithelial cells [23,44] in patients with IBS.
Hypoxanthine is reported to promote intestinal barrier function and may, as a substrate for
oxidase activity, play a role in IBS pathophysiology [43,45]. Indeed, IBS patients have been
reported to display altered hypoxanthine levels, although results are inconclusive [18,26].
Still, the as yet scarce and somewhat inconsistent data of hypoxanthine in IBS highlight
the complexity of this metabolic pathway, but also suggest that it may be of importance
for underlying disease mechanisms. Moreover, our LASSO-extracted variables provided
a refined discriminatory model, further implicating the importance of certain metabolic
pathways such as the amino acid and purine metabolism. Altogether, our findings suggest
that IBS patients may present alterations in their intestinal metabolic function and activity
that could play an important role in the pathophysiology of IBS.
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Growing evidence further indicates that IBS pathogenesis involves a dysregulated and
bidirectional gut-brain interaction where microbiota and microbial metabolites influence
neuro-immune crosstalk [1,20,46], and in return, the central nervous system influences the
intestinal microenvironment [1]. A recent study demonstrated altered profiles of urine
metabolites and faecal bacteria in IBS, and with specific correlations with anxiety and
depression [20]. Even though the intestinal microenvironment profile defined in this study
could not discriminate patients based on IBS severity or psychological symptoms, the
detection of increased abundance of molecules related to neuro-immune signalling, such
as tryptophan, ornithine, glycine and glutamic acid, may support an underlying perturbed
gut-brain interaction in patients with IBS. Tryptophan, an intermediate metabolite in sero-
tonin metabolism, has been suggested to be essential for the proliferation and effector
functions of T cells [47] and the enhancement of serotonin production. Serotonin may
regulate the activity of innate immune cells through interaction with receptors in mast cells,
dendritic cells and macrophages/monocytes. Furthermore, microbial tryptophan catabo-
lites are known to activate gut immune response via the aryl hydrocarbon receptor [48],
potentially strengthening the intestinal barrier integrity [49]. Thus, an altered tryptophan
metabolism may contribute to the aberrant host–microbial crosstalk associated with IBS
patients. In addition, we also recorded increased levels of ornithine and its precursor
glutamic acid in IBS patients. Both molecules are known to participate in the synthesis
of polyamines as putrescine, spermidine and spermine, with a suggested importance in
lymphocyte activation and development [50]. Moreover, tryptophan, glycine and gluta-
mate which are metabolites involved in amino acid metabolism, have also been associated
with IBS-specific brain changes in a recent study integrating functional neuroimaging and
faecal metabolites [51]. All in all, these findings support the importance of metabolites in
the aberrant brain–gut interaction implicated in the pathophysiology of IBS, warranting
further investigations.
The IPA core analysis was carried out to evaluate the direction of the change in the
metabolomic profile and predict effects on biological functions in IBS patients compared to
healthy subjects. Interestingly, IPA further predicted the uptake of various amino acids to
be altered in IBS patients, similarly to studies proposing differences in the ability of IBS pa-
tients to metabolize dietary substrates [23]. Additionally, the altered amino acid uptake may
be associated with IBS-specific dietary habits suggested to be characterized by an increased
protein and dietary fibre intake [52], although studies are inconclusive [53]. Additionally,
apoptosis and cell death of epithelial cells were predicted to be increased in patients with
IBS, supporting the notion of an impaired epithelial barrier in IBS pathophysiology [6]. It is
also important to point out that the interactions between the intestinal microenvironment
and the host are complex and multidimensional. Even though our results predict changes
in several biological functions potentially associated with IBS disease pathophysiology,
further metaproteomic analyses would provide supplementary functional information
which would enhance the biological meaning of such distinct intestinal microenvironment.
In line with this, a recent study identified peptides from potentially pathogenic Brachyspira
in a subset of patients with IBS using metaproteomics, as well as described the immune
response associated with this infection [54].
Additionally, our results suggest a relationship between bowel habits and the in-
testinal microenvironment, where a potential shift in microbial function rather than the
microbial composition may be of importance and reflect an altered faecal metabolite profile
in IBS subtypes. The separation between IBS-D and IBS-C patients was primarily attributed
to higher levels of succinic acid, nicotinic acid and xanthine, which are involved in energy
metabolism-related pathways. Similar to findings from Lee et al. [18], higher levels of
tryptophan were also depicted in IBS-D patients. Tryptophan, as described above, is an
intermediate metabolite in serotonin metabolism. Serotonin is known to promote motil-
ity, secretion and visceral hypersensitivity in IBS patients with diarrhoea [18,42,55] and,
hence, drug development has to a large extent focused on 5-hydroxytryptamine (5-HT)
receptor antagonist for symptom management [55]. Moreover, altered levels of trypto-
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phan and putrescine observed in IBS-D could be implicated in symptom generation of
abdominal pain and discomfort [56]. Overall, the distinct intestinal microenvironment as-
sociated with IBS-D patients described in our study is consistent with the current available
literature [21,25,26].
While metabolites had greater influence when discriminating between IBS patients
and healthy subjects, a few bacterial taxa were identified to be linked to health whereas
others were associated with the IBS-specific profile. For instance, IBS patients had lower
abundance of Clostridium sp. levels, suggested to be relevant in gut health [57]. A previous
study has also associated members of Clostridiales including Clostridium sp., with GI sen-
sorimotor function in healthy controls, but not in IBS patients [58]. These differences have
been suggested to contribute to the altered brain-gut-microbe interaction and pain percep-
tion in patients with IBS [58]. Moreover, a higher abundance of Firmicutes, Escherichia spp.
and Shigella sp. and Mycoplasma homini was a distinct feature of IBS-C patients in our study.
These bacterial taxa have previously been associated with IBS, however not to any specific
IBS subtype [14,59,60]. Altogether these results suggest that these different taxa may be
associated with the predominant bowel habits in IBS patients.
Previous reports evaluating the effects of faecal microbiota transplantation (FMT)
from healthy subjects, described that FMT normalized either microbiota [61] or microbiota
together with short-chain fatty acids [62] in IBS-D patients and improved IBS symptoms.
Altogether, these studies highlight differences in the intestinal microenvironment of IBS
and further support the necessity to account for the role of both microbiota and metabolites
when investigating new microbiota-based treatments for IBS management.
Although presenting promising results, this study has its limitations and weaknesses.
First of all, human microbiome studies have raised concerns regarding the contribution of
age and gender in the human gut microbiota [63]. Nevertheless, in spite of this retrospective
study with limited study size was not matched for age and gender, this did not influence our
findings. Moreover, dietary habits which can affect both the gut microbiota and metabolite
composition [64] were not taken into account. Although this study collected only single
time-point samples, longitudinal sampling has been shown to overcome heterogeneity and
improve accuracy of results [26], and it would be a beneficial add on for future validation
studies. Further, correction for stool water content or even the addition of a second healthy
control group with an accelerated transit triggered by laxatives would have been valuable
to support the effect of bowel habit on the intestinal microenvironment, as depicted in
our study. Despite the limitations of the selected heterogeneous IBS cohort, we could
demonstrate that a mixed IBS cohort could be differentiated from healthy subjects based
on their intestinal microenvironment. Altogether, our study highlights the importance
of the combined microbiota and metabolite profile in improving the ability to separate
IBS patients and healthy subjects, and our refined model based on the LASSO selected
variables provides possibilities for future explorative studies.
In conclusion, IBS appears to be associated with a shift in microbial function rather
than microbial composition, with bowel habits also being reflected in the intestinal mi-
croenvironment profile of IBS patients. Accordingly, intestinal microenvironment profiling
through measurement of specific faecal microbes and metabolites may be considered
as a future non-invasive diagnostic tool alongside providing valuable insights into the
pathophysiology of IBS.
Supplementary Materials: The following are available online at https://www.mdpi.com/article
/10.3390/cells10061459/s1, Supplementary Methods: Symptom Assessment Questionnaires; and
Selection of variables from the intestinal microenvironment profile, Figure S1: Faecal microbiota and
metabolite profiles of IBS patients and healthy subjects, Figure S2: Cleveland dot plot representing
the distinct combined microbiota and metabolite profile in IBS patients and healthy subjects, Table
S1: Significantly enriched functions predicted by Ingenuity Pathway Analysis (IPA) “Core analysis”.
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